Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 ...
Nestle's GLP-1 'shot,' the FDA's Zepbound ruling, and Ozempic lures people to the doctor: Pharma news roundup
Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...
Engineering News-Record15h
2024 Global Sourcebook: Producing Treatments for Rare Diseases
Danish pharmaceutical company Novo Nordisk recently announced plans to spend approximately $1.2 billion to build a new ...
NJBIZ16h
EU reportedly reviewing link between Ozempic, rare eye disease
With U.S. headquarters in Plainsboro, Novo Nordisk told NJBIZ, "NAION is a very rare eye disease, and it is not an adverse ...
24/7 Wall St20h
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
EurekAlert!1d
American Society for Nutrition
The American Society for Nutrition Foundation (ASNF) and the Novo Nordisk Foundation (NNF), two philanthropic 501(c)(3) organizations, have joined forces to launch new awards to celebrate excellence ...
Novo Nordisk Completes Strategic Acquisition to Enhance Manufacturing Capacity
Novo Nordisk ( (NVO) ) has provided an announcement.
Novo Nordisk's Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease
New studies link diabetes drug Ozempic to increased risk of NAION, a rare eye condition causing vision loss. Danish Medicines ...
EU Drug Regulator to Review Ozempic's Possible Link to Eye Condition — Update
The European Union's drug regulator said it would review a potential link between Novo Nordisk's blockbuster diabetes drug, Ozempic, and a rare eye condition that causes vision loss after recent ...